Literature DB >> 15364184

History of thymoma and yellow fever vaccination.

Rachel Barwick Eidex1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15364184     DOI： 10.1016/S0140-6736(04)17017-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  25 in total

1.  Mapping the risk of yellow Fever infection.

Authors:  David R Hill
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

2.  Defining risk groups to yellow fever vaccine-associated viscerotropic disease in the absence of denominator data.

Authors:  Stephen J Seligman; Joel E Cohen; Yuval Itan; Jean-Laurent Casanova; John C Pezzullo
Journal:  Am J Trop Med Hyg       Date:  2014-01-06       Impact factor: 2.345

Review 3.  Advances and controversies in yellow fever vaccination.

Authors:  Emile F F Jonker; Leonardus G Visser; Anna H Roukens
Journal:  Ther Adv Vaccines       Date:  2013-11

4.  JC virus identified in a patient with persistent and severe West Nile virus disease.

Authors:  Neta S Zuckerman; Victoria Indenbaum; Ron Milo; Ella Mendelson; Yaniv Lustig
Journal:  J Neurovirol       Date:  2019-04-04       Impact factor: 2.643

5.  Suspected yellow fever vaccine-associated viscerotropic adverse events (1973 and 1978), United States.

Authors:  Thomas P Monath
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

6.  STATEMENT FOR TRAVELLERS AND YELLOW FEVER: An Advisory Committee Statement (ACS) Committee to Advise on Tropical Medicine and Travel (CATMAT).

Authors:  This Statement Was Prepared By P Charlebois
Journal:  Can Commun Dis Rep       Date:  2013-03-05

7.  Statement for Travellers and Yellow Fever: Committee to Advise on Tropical Medicine and Travel.

Authors:  P Charlebois
Journal:  Can Commun Dis Rep       Date:  2010-10-02

Review 8.  Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.

Authors:  Theodoros Kelesidis; Otto Yang
Journal:  Clin Immunol       Date:  2010-02-10       Impact factor: 3.969

9.  Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.

Authors:  Maria Luiza Silva; Luçandra Ramos Espírito-Santo; Marina Angela Martins; Denise Silveira-Lemos; Vanessa Peruhype-Magalhães; Ricardo Carvalho Caminha; Péricles de Andrade Maranhão-Filho; Maria Auxiliadora-Martins; Reinaldo de Menezes Martins; Ricardo Galler; Marcos da Silva Freire; Rugimar Marcovistz; Akira Homma; Dirk E Teuwen; Silvana Maria Elói-Santos; Mariléia Chaves Andrade; Andréa Teixeira-Carvalho; Olindo Assis Martins-Filho
Journal:  Clin Vaccine Immunol       Date:  2009-11-11

10.  A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.

Authors:  Srilatha Edupuganti; Rachel B Eidex; Harry Keyserling; Rama S Akondy; Robert Lanciotti; Walter Orenstein; Carlos del Rio; Yi Pan; Troy Querec; Harvey Lipman; Alan Barrett; Rafi Ahmed; Dirk Teuwen; Martin Cetron; Mark J Mulligan
Journal:  Am J Trop Med Hyg       Date:  2012-12-03       Impact factor: 2.345
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.